Haitron "Acquires $13.8 Million Worth of Shares in U.S. Subsidiary"
Haitron announced on the 5th that it will acquire 3,333,333 shares of Exicure, a U.S. nucleic acid therapeutic drug development company, for approximately 13.8 billion KRW.
After acquiring the shares, the ownership stake will be 60.5%. The scheduled date for the stock acquisition is the 14th.
Hot Picks Today
"Can't Hold On Any Longer" 80,000 Stores Shut Down... The Fall of China’s Bakeries That Relied on SNS Buzz
- "Unknown Sources of Infection"... Ebola Death Toll Nears 1,000 as Outbreak Spirals in DR Congo
- Fired Over a $2 Snack: Why a 300 Million KRW Engineer Lost His Job
- South Korean Wins KRW 5.8 Billion Lottery While Working in Vietnam: "Checked the Numbers Several Times"
- "Joey Wong Returns After 22 Years: The Secret Behind Her Unchanging Beauty"
Haitron stated that the purpose of this stock acquisition is a "paid-in capital increase for business expansion."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
